AOD-9604: Side Effects & Safety

AOD-9604 is a synthetic modified analog of the C-terminal fragment of human growth hormone (specifically hGH 176-191) developed by Australian company Metabolic Pharmaceuticals through the 1990s and 2000s. The molecule was engineered to retain hGH's lipolytic effect while removing its growth-promoting and diabetogenic effects.^[1] This safety-by-design lineage is the most important context for understanding its side-effect profile.

Metabolic Pharmaceuticals completed six Phase 1 and three Phase 2 / 2b trials in humans (including a 12-week Phase 2b in 502 obese adults) before discontinuing development for failing to meet its primary efficacy endpoint of weight loss superior to placebo at 12 weeks. Importantly, the trials did not stop for safety — the safety profile was consistently favorable across all trials.^[2]

In 2014, AOD-9604 received FDA Generally Recognized as Safe (GRAS) status as a food ingredient, allowing inclusion in functional foods and beverages.^[3] GRAS status is not the same as drug approval, but it does require extensive toxicology data and is one of the most relevant US regulatory benchmarks for this peptide. AOD-9604 is not on the agenda for the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting.

Effect	Frequency in Phase 2b	Mechanism	Management
Injection-site redness / mild irritation	Most common (~10–20%)	Local immune response	Rotate sites; resolves within 24–48 hours
Headache	Reported, low frequency	Likely incidental	Hydrate; self-limiting
Mild nausea	Reported, low frequency	Unclear; uncommon	Take with food
Fatigue	Reported, low frequency	Unclear	Self-resolves within first week
Antibody formation	Not detected	Native sequence	No clinical consequence observed
Hypoglycemia	Not observed	Lacks IGF-1 effect	N/A
Joint pain / carpal tunnel	Not observed	Lacks growth effects of full hGH	N/A

Across all Phase 1 and 2 trials, the safety signal was indistinguishable from placebo apart from local injection-site effects. No serious adverse events attributable to AOD-9604 were reported.^[2]

Full human growth hormone (somatropin) has a well-documented side-effect profile: fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, IGF-1 elevation, and theoretical cancer concerns from sustained IGF-1 exposure. AOD-9604 was engineered to avoid these by isolating only the lipolytic fragment.

• No IGF-1 elevation: AOD-9604 does not signal through the GH receptor in the same way as full hGH. IGF-1 levels in clinical trials remained at baseline.^[1]
• No insulin resistance: fasting glucose and insulin sensitivity remained unchanged in the Phase 2b 502-patient trial.^[2]
• No growth effects on existing tissue: no organ enlargement, no skeletal changes, no carpal tunnel signal.
• No demonstrable anabolic effect on muscle: a tradeoff — patients did not gain or lose muscle mass.

• Pregnancy and breastfeeding: no controlled human pregnancy data. Standard advice is to avoid all peptides during pregnancy and breastfeeding.
• Children and adolescents: not studied in pediatric populations. Not recommended outside trials.
• Active malignancy: although AOD-9604 lacks the IGF-1 effects that drive most oncology concerns with hGH, the precautionary principle applies — discuss with oncology before use.
• Severe renal or hepatic impairment: not studied; peptide elimination pathway not fully characterized.
• Known allergy or hypersensitivity to the molecule or formulation excipients.

Drug interactions

No well-characterized clinical drug interactions exist for AOD-9604 at typical research doses. It does not affect CYP450 substrates. Theoretical caution with concurrent insulin or sulfonylurea use (though no clinical hypoglycemia signal has been observed).

• Persistent injection-site reaction beyond 72 hours: rotate sites, evaluate technique (see injection technique guide), and consider lower frequency or alternate route.
• Headache or fatigue beyond first week: reduce dose by 50% for 3–5 days. If it persists, discontinue and seek evaluation.
• Allergic reaction (rash, hives, breathing difficulty): discontinue immediately and seek emergency care.
• Unexplained systemic symptoms: stop and evaluate. AOD-9604 has a very benign profile, so new systemic symptoms warrant a search for another cause.

See the AOD-9604 complete guide, dosage protocols, and peptides for fat loss.